Find here all our blog posts tagged with: regulatory strategy.

Three distinct colored light paths converging on an abstract glowing medical device against a dark background.

Three Regulators, Three Different Bets on AI Medtech

The EU, the US, and China are sequencing AI device oversight in opposite orders, and compliance leaders need to plan for all three.

An empty clinical trial room lit in blue with abstract projected data lines on the wall.

The Trial Floor Is the Next Oversight Line, Not the Device Shelf

FDA's closed RFI on AI-enabled early-phase trials signals a second oversight track distinct from device review, and sponsors are moving faster than either.

Aerial view of three distinct currents flowing side by side without merging, symbolizing separate regulatory tracks that have not yet converged.

The Convergence Gap in AI Life Sciences Regulation

Regulators describe AI, digital health, and clinical trial law as converging, but FDA, UK, and Chinese actions show the frameworks are still moving on separate, misaligned tracks.

A half-built institutional archive of steel shelving and scaffolding lit by a single shaft of light, symbolizing regulatory infrastructure under construction.

FDA Is Assembling the Machinery Before It Finishes the Rule

FDA's device review architecture and new leadership roles point toward trial-side AI scrutiny, though the timeline and scope remain genuinely unsettled.

Two shifting translucent glass panels overlapping in a clinical white laboratory space, symbolizing two regulatory frameworks being revised in parallel.

Europe's AI Act and MDR Are Being Rewritten at the Same Time

European regulators are revising the AI Act and MDR simultaneously, leaving life sciences compliance teams no stable baseline to build against.

A partially disassembled clock with exposed gears standing in a sterile hospital corridor, symbolizing misaligned regulatory timelines.

The EU AI Act Reprieve Is a Timing Bet, Not a Pause

Digital Omnibus alignment gives AI-enabled medical devices breathing room on paper, but MDR/IVDR certification obligations have not moved and neither has the underlying risk.

Two interlocking translucent gears symbolizing overlapping regulatory systems for clinical AI in Europe

Europe's Dual Certification Trap for Clinical AI

AI systems that influence clinical decisions can trigger MDR and EU AI Act obligations at once, and the Digital Omnibus timeline does not change that exposure.

Scaffolding and steel framework around a partially built structure at dusk, symbolizing a regulatory system still under construction.

FDA's Postmarket AI Machinery Is Still Under Construction

Recent FDA moves on AI-enabled devices signal a postmarket framework taking shape, but the agency's own uncertainty argues against treating early engagement as a settled strategy.

A human hand and a mechanical hand reach toward each other under clinical light, symbolizing shared judgment between physicians and AI systems.

The Comment Window That Will Define GenAI Medical Devices

FDA's open docket on generative AI medical devices is the narrow window life sciences leaders have to shape binding rules before they harden.

Abstract image of a clinician's hand meeting a translucent data structure in a softly lit hospital corridor, symbolizing continuous performance evaluation.

The FDA's Open Docket Is the Real Deadline

FDA's move toward assessing generative AI devices like clinicians raises real feasibility questions, but sponsors who wait for guidance will lose the argument.

Abstract streams of glowing data particles converging into a single current against a dark clinical backdrop.

Routine Health Data Is Fueling AI Devices Faster Than FDA Can Define the Standard

FDA's December 2025 real-world evidence guidance lets sponsors train AI devices on routine health data, but provenance and bias standards remain undefined.

An empty executive office corridor lit by a single desk lamp, evoking a leadership transition inside a regulatory agency.

FDA's New Deputy Commissioner Post Is the Real AI Signal

HHS is creating a dedicated technology leadership role at FDA, and that appointment will shape AI device oversight more than any single guidance document.

Three interlocking mechanical clocks running at different speeds, symbolizing misaligned regulatory timelines for AI-enabled medical devices.

Three Regulators, Three Clocks, One AI-Enabled Device

The EU, US, and China are each running statute ahead of certification infrastructure for AI-enabled medical devices, and manufacturers need one documentation architecture, not three.

Three colored channels of a river diverging and reconverging under a misty dawn sky, symbolizing parallel regulatory pressures on a single timeline.

MDUFA VI Is a Capacity Signal, Not the Whole Story

The MDUFA VI negotiation matters for AI device review capacity, but sponsors treating it as the sole variable are missing parallel forces already shaping their timelines.

A stationary regulatory rulebook against a blur of fast-moving digital data trails, symbolizing regulation lagging AI velocity.

The Guidance Cannot Outrun the Model

FDA and EU regulators are structurally too slow to govern AI at the pace it changes, so life sciences compliance leaders must build internal governance now.

Abstract image of a surgeon's hands beneath a shifting holographic light field above an operating table, symbolizing AI surgical guidance in transition between regulatory categories.

Surgical AI's Classification Is a Bet, Not a Badge

Medtronic's Aide platform is cleared as a low-risk data system, but AI-assisted surgery is moving toward active guidance faster than that classification can hold.

Abstract split image contrasting a clear, resolved network pathway with a dense, unresolved tangle of nodes, symbolizing divergent regulatory progress in life sciences AI.

Life Sciences AI Is Moving at Two Different Speeds

Diagnostic AI is clearing FDA review on schedule while AI-native drug discovery still has zero approvals, and the gap is documentation, not science.

Two diverging paths of light, one narrow and bounded and one diffuse and branching, symbolizing split regulatory tracks for medical AI

Two Speeds of FDA AI Clearance

The FDA's bounded-diagnostic clearances and its generative-AI comment period reveal a widening split in medical AI oversight that regulated buyers must plan around now.